• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, October 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

NIFTY® DNBSEQ-G99 platform receives CE-IVDD certification and advances prenatal care standards

Bioengineer by Bioengineer
February 22, 2024
in Health
Reading Time: 2 mins read
0
NIFTY® DNBSEQ-G99 Platform CE-IVDD Certification
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

BGI Europe A/S, a wholly owned subsidiary of BGI Genomics, announced its NIFTY® non-invasive prenatal testing kit and software (CE-IVDD List B) were granted an extension under its existing CE-IVDD certification to include the DNBSEQ-G99 model to meet the European Union regulations for medical devices.

NIFTY® DNBSEQ-G99 Platform CE-IVDD Certification

Credit: BGI Genomics

BGI Europe A/S, a wholly owned subsidiary of BGI Genomics, announced its NIFTY® non-invasive prenatal testing kit and software (CE-IVDD List B) were granted an extension under its existing CE-IVDD certification to include the DNBSEQ-G99 model to meet the European Union regulations for medical devices.

In January 2024, BGI Genomics unveiled the NIFTY® ultra-fast non-invasive prenatal genetic testing product, utilizing the innovative DNBSEQ-G99 platform. Designed for both small and medium throughput, this platform ensures top-notch testing performance and quality. It enables clinical laboratories to provide quicker and more accurate prenatal genetic testing results. This advancement is crucial for timely genetic counseling and further prenatal diagnosis, enhancing prenatal care options.

Key Features of the DNBSEQ-G99 Platform:

Speed: The DNBSEQ-G99 platform dramatically reduces sequencing time to just 3 hours, with the entire process from sample collection to report generation taking only 14 hours. This efficiency significantly reduces the anxious wait for expecting families.

Flexibility: It allows for the processing of varying sample sizes in a single run, accommodating a minimum of 12 samples. This flexibility helps in minimizing reagent waste and cutting costs.

Versatility: The platform supports various sequencing modes and is suitable for a wide range of tests, including pre-embryo transplantation chromosome testing and monogenic disease carrier screening.

Simplicity: Featuring a cassette flow cell and an innovative pre-injected reagent design, the DNBSEQ-G99 simplifies the sequencing process, making it user-friendly for operators.

BGI Genomics has been a pioneer in non-invasive prenatal genetic testing since 2010. NIFTY® has received medical device qualifications in various countries, including the United Kingdom, Australia, Saudi Arabia, Turkey, India, and Thailand. BGI Genomics continues to upgrade its prenatal and neonatal tests, contributing to better public health systems and outcomes.

Guided by the vision of “Omics for all,” BGI Genomics is dedicated to enhancing genetic testing technologies, thereby advancing global precision medicine and improving lives.

About BGI Genomics

BGI Genomics, headquartered in Shenzhen, China, is the world’s leading integrated solutions provider of precision medicine. To learn more about the NIFTY® Test – the world’s leading non-invasive prenatal test (NIPT), please see this webpage. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.



Share12Tweet8Share2ShareShareShare2

Related Posts

Multimedia Measurements Reveal PFAS Exposure at Home

October 2, 2025

Sure! Here’s a rewritten version of the headline tailored for a science magazine post about Bronchiectasis and NTM Research Registry data presented at the European Respiratory Society Congress: “New Insights into Bronchiectasis and NTM Infections Unveiled from Research Registry Data at European Respiratory Society Congress” If you want, I can also help rewrite the two abstracts themselves or create a more detailed magazine-style summary based on them. Just let me know!

October 2, 2025

Platelet Activation Drives Inflammation in Myasthenia Gravis

October 2, 2025

The RESTART Trial Explores Drug Targeting Toxic HIV Protein

October 2, 2025

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    91 shares
    Share 36 Tweet 23
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    77 shares
    Share 31 Tweet 19
  • Physicists Develop Visible Time Crystal for the First Time

    74 shares
    Share 30 Tweet 19
  • How Donor Human Milk Storage Impacts Gut Health in Preemies

    64 shares
    Share 26 Tweet 16

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Study Reveals Sudan Ebola Virus Can Persist for Months in Survivors, Finds WSU Researchers

Multimedia Measurements Reveal PFAS Exposure at Home

Prognostic Factors in Advanced Cervical Cancer

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 60 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.